Compare LMAT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | TRVI |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2006 | 2019 |
| Metric | LMAT | TRVI |
|---|---|---|
| Price | $83.21 | $11.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $101.83 | $20.38 |
| AVG Volume (30 Days) | 177.9K | ★ 1.8M |
| Earning Date | 02-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ 27.40 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $240,866,000.00 | N/A |
| Revenue This Year | $15.17 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $36.00 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $71.42 | $3.47 |
| 52 Week High | $105.55 | $14.39 |
| Indicator | LMAT | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 37.18 |
| Support Level | $79.40 | $10.58 |
| Resistance Level | $86.00 | $13.16 |
| Average True Range (ATR) | 2.22 | 0.64 |
| MACD | 0.06 | -0.24 |
| Stochastic Oscillator | 49.69 | 27.27 |
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.